Maria Holyanova is the National Manager of Brand & Marketing at her organization. She focuses on topics related to psychedelics, cannabis, and data, with a particular interest in developments in New York and Colorado. Maria's insights and expertise have been featured in 420 Magazine and Psychedelic Spotlight.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Maria Holyanova's coverage primarily focuses on scientific and healthcare aspects of psychedelics, particularly in the context of clinical trials, mental health, and regulatory developments. She frequently covers news related to psilocybin and its impact on depression.
Given Maria’s focus on clinical trials and regulatory developments in psychedelic research, she would likely be interested in receiving pitches from experts involved in conducting or analyzing such trials. Researchers with insights into the effects of psychedelics on mental health could also be valuable sources for her articles.
It is important to note that Maria does not appear to have a specific geographic focus but rather covers international developments within the psychedelic research space. Therefore, relevant experts from any location may find success reaching out to her with compelling information or expertise regarding ongoing studies or legal changes related to psychedelics.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Maria Holyanova
The debate now is the importance of psychological support in trials investigating psychedelic-assisted therapy.
While everyone was preparing to head to Wonderland Miami, the psychedelic space saw a week full of debates! From the FDA's recommendation to limit psy
By: Maria Holyanova
Psilocybin can be an useful tool when it comes to reducing nicotine withdrawal, PTSD, and even OCD symptoms. It could also be a hazardous weapon for t
By: Maria Holyanova
Psilocybin use shows reduced psychological distress in individuals with adverse childhood experiences, while microdosing shows a "both and" approach t
By: Maria Holyanova
In the event you begin experiencing signs of tetany during a trip and a simple bottle of water isn't sufficient to reduce symptoms, you should conside
While yet another study shows psilocybin's efficacy in treating depression in cancer patients, and 2024 presidential candidates push for a psychedelics reform from all sides, Colorado public health officials fight over manure.
As MDMA nears FDA approval, LSD's efficacy in treating generalized anxiety disorder is demonstrated in MindMed's Phase 2b study. Meanwhile, Congress has approved a psychedelic treatment bill for active duty service members suffering from PTSD.
If approved, MDMA-assisted therapy would be the first psychedelic-assisted therapy, which drive new investment into research in mental health.
The evidence pile for psilocybin’s efficacy in treating depression is growing with new data demonstrating 79% remission rates after two doses. Meanwhile, early trials hint at MEAI’s efficacy in treating obesity, ketamine studies suggest a single dose is effective in treating anxiety and discussions arise about psychedelic use and its capacity to birth new environmentalists.
(833) 317-6278 
